

ORIGINAL ARTICLE

Common variant at 16p11.2 conferring risk of psychosis

S Steinberg¹, S de Jong², M Mattheisen^{3,4,5}, J Costas⁶, D Demontis^{7,8}, S Jamain^{9,10}, OPH Pietiläinen^{11,12,13}, K Lin¹⁴, S Papiol^{15,16}, J Huttenlocher^{1,17}, E Sigurdsson^{18,19}, E Vassos²⁰, I Giegling²¹, R Breuer²², G Fraser²³, N Walker²⁴, I Melle²⁵, S Djurovic²⁵, I Agartz²⁵, A Tuulio-Henriksson²⁶, J Suvisaari²⁶, J Lönnqvist²⁶, T Paunio²⁷, L Olsen²⁸, T Hansen²⁸, A Ingason²⁸, M Pirinen²⁹, E Strengman³⁰, GROUP³¹, DM Hougaard³¹, T Ørntoft³², M Didriksen³³, MV Hollegaard³¹, M Nordentoft^{8,34}, L Abramova³⁵, V Kaleda³⁵, M Arrojo³⁶, J Sanjuán³⁷, C Arango³⁸, B Etain^{9,10,39}, F Bellivier^{9,10,39,40}, A Méary^{9,10,39}, F Schürhoff^{9,10,39,40}, A Szoke^{9,10,39}, M Ribolsi⁴¹, V Magni⁴¹, A Siracusano⁴¹, S Sperling¹⁶, M Rossner^{15,42}, C Christiansen⁴³, LA Kiemeny⁴⁴, B Franke⁴⁵, LH van den Berg⁴⁶, J Veldink⁴⁶, S Curran^{20,47}, P Bolton^{20,47}, M Poot³⁰, W Staal⁴⁸, K Rehnstrom^{11,13}, H Kilpinen^{11,13}, CM Freitag⁴⁹, J Meyer⁵⁰, P Magnusson⁵¹, E Saemundsen⁵², I Martsenkovsky⁵³, I Bikshaieva⁵³, I Martsenkovska⁵³, O Vashchenko⁵³, M Raleva⁵⁴, K Paketchieva⁵⁴, B Stefanovski⁵⁴, N Durmishi⁵⁴, M Pejovic Milovancevic^{55,56}, D Lecic Tosevski^{55,56}, T Silagadze⁵⁷, N Naneishvili⁵⁷, N Mikeladze⁵⁷, S Surguladze⁵⁸, JB Vincent⁵⁹, A Farmer²⁰, PB Mitchell^{60,61}, A Wright^{60,61}, PR Schofield^{62,63}, JM Fullerton^{62,63}, GW Montgomery⁶⁴, NG Martin⁶⁴, IA Rubino⁴¹, R van Winkel^{65,66}, G Kenis⁶⁶, M De Hert⁶⁵, JM Réthelyi⁶⁷, I Bitter⁶⁷, L Terenius⁶⁸, EG Jönsson⁶⁸, S Bakker⁶⁹, J van Os⁷⁰, A Jablensky⁷¹, M Leboyer^{9,10,39,40}, E Bramon⁷², J Powell¹⁴, R Murray⁷³, A Corvin⁷⁴, M Gill⁷⁴, D Morris⁷⁴, FA O'Neill⁷⁵, K Kendler^{76,77,78}, B Riley^{76,77,78}, Wellcome Trust Case Control Consortium 2⁹¹, N Craddock⁷⁹, MJ Owen⁷⁹, MC O'Donovan⁷⁹, U Thorsteinsdottir^{1,19}, A Kong¹, H Ehrenreich^{15,16}, A Carracedo⁸⁰, V Golimbet³⁵, OA Andreassen²⁵, AD Børglum^{7,8,81}, O Mors^{8,81}, PB Mortensen^{8,82}, T Werge^{8,28}, RA Ophoff^{2,69}, MM Nöthen^{83,84}, M Rietschel²², S Cichon^{5,84,85}, M Ruggeri⁸⁶, S Tosato⁸⁶, A Palotie^{11,13,87,88}, D St Clair²³, D Rujescu^{21,89}, DA Collier^{20,90}, H Stefansson¹ and K Stefansson^{1,19}

¹deCODE genetics, Reykjavik, Iceland; ²Center for Neurobehavioral Genetics, UCLA, Los Angeles, CA, USA; ³Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ⁴Institute for Genomic Mathematics, University of Bonn, Bonn, Germany; ⁵Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany; ⁶Galician Foundation of Genomic Medicine-SERGAS, Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain; ⁷Department of Biomedicine, Human Genetics, and Centre for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, Denmark; ⁸The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark; ⁹Fondation FondaMental, Créteil, France; ¹⁰INSERM U 955, Psychiatrie Génétique, Créteil, France; ¹¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland; ¹²Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland; ¹³Wellcome Trust Sanger Institute, Cambridge, UK; ¹⁴Department of Neuroscience, NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King's College, London, UK; ¹⁵DFG Research Center for Molecular Physiology of the Brain (CMPB), Göttingen, Germany; ¹⁶Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany; ¹⁷Department of Medical Genetics, Institute of Human Genetics, University of Tübingen, Tübingen, Germany; ¹⁸Department of Psychiatry, National University Hospital, Reykjavik, Iceland; ¹⁹School of Medicine, University of Iceland, Reykjavik, Iceland; ²⁰Social, Genetic and Developmental Psychiatry Research Centre, Institute of Psychiatry, King's College, London, UK; ²¹Division of Molecular and Clinical Neurobiology, Department of Psychiatry, Ludwig-Maximilians University, Munich, Germany; ²²Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany; ²³Department of Mental Health, University of Aberdeen, Royal Cornhill Hospital, Aberdeen, UK; ²⁴Ravenscraig Hospital, Greenock, UK; ²⁵Division of Mental Health and Addiction, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway; ²⁶Department of Mental Health and Substance Abuse Services, National Institute for Health and Welfare, Helsinki, Finland, and Department of Psychiatry, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; ²⁷Public Health Genomics Unit, National Institute for Health and Welfare THL, Helsinki, Finland, and Department of Psychiatry, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; ²⁸Institute of Biological Psychiatry, Mental Health Centre Sct Hans, Copenhagen University, Roskilde, Denmark; ²⁹Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK; ³⁰Department of Medical Genetics, University Medical Centre Utrecht, Utrecht, the Netherlands; ³¹Section of Neonatal Screening and Hormones, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, Denmark; ³²Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; ³³Synaptic transmission, H. Lundbeck A/S, Copenhagen, Denmark; ³⁴Psychiatric Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark; ³⁵Mental Health Research Center, Russian Academy of Medical Sciences, Moscow, Russia; ³⁶Service of Psychiatry, Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain; ³⁷Unit of Psychiatry, Faculty of Medicine, University of Valencia, Network Center of Biomedical Research on Mental Health (CIBERSAM), Valencia, Spain; ³⁸Hospital General Universitario Gregorio Marañón, IISGM, Universidad Complutense, CIBERSAM, Madrid, Spain; ³⁹AP-HP, Hôpital H. Mondor – A. Chenevier, Pôle de Psychiatrie, Creteil France; ⁴⁰Université Paris Est, Faculté de Médecine, Creteil, France; ⁴¹Section of Psychiatry, Department of Neuroscience, University of Rome-Tor Vergata, Rome, Italy; ⁴²Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen, Germany; ⁴³Nordic Bioscience, Herlev, Denmark; ⁴⁴Department of Epidemiology and Biostatistics and Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; ⁴⁵Departments of Human Genetics and Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; ⁴⁶Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center, Utrecht, the Netherlands; ⁴⁷Department of Child and Adolescent Psychiatry, Institute of Psychiatry, King's College, London UK; ⁴⁸Department of Cognitive Neuroscience, Radboud University Nijmegen, Nijmegen, The Netherlands; ⁴⁹Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Frankfurt am Main, Frankfurt am Main, Germany; ⁵⁰Department of Neurobehavioural Genetics, University of Trier, Trier, Germany; ⁵¹Department of Child and Adolescent Psychiatry, National University Hospital, Reykjavik, Iceland; ⁵²State Diagnostic and Counseling Centre, Kopavogur, Iceland; ⁵³Department of Child, Adolescent Psychiatry and Medical-Social Rehabilitation, Ukrainian Research Institute of Social, Forensic Psychiatry and Drug Abuse, Kyiv, Ukraine; ⁵⁴Department of Child and Adolescent Psychiatry, University of Skopje, Skopje, Macedonia; ⁵⁵Institute of Mental Health, Belgrade, Serbia; ⁵⁶Medical Faculty, University of Belgrade, Belgrade, Serbia; ⁵⁷Department of Psychiatry and Drug Addiction, Tbilisi State Medical University (TSMU), Tbilisi, Georgia; ⁵⁸Social and Affective Neuroscience Lab, Ilia State University, Tbilisi, Georgia; ⁵⁹Molecular Neuropsychiatry and Development Laboratory, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada; ⁶⁰Black Dog Institute, Prince of Wales Hospital, Randwick, NSW, Australia; ⁶¹School of Psychiatry, University of New South Wales, Sydney, NSW, Australia; ⁶²Neuroscience Research Australia, Barker Street, Sydney, NSW, Australia; ⁶³School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia; ⁶⁴Queensland Institute of Medical Research, Brisbane, QLD, Australia; ⁶⁵University Psychiatric Center, Catholic University Leuven, Kortenberg, Belgium; ⁶⁶Department of Psychiatry and Psychology, School of Mental Health and Neuroscience, European Graduate School of Neuroscience (EURON), South Limburg Mental Health Research and Teaching Network (SEARCH), Maastricht University Medical Center, Maastricht, The Netherlands; ⁶⁷Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary; ⁶⁸Department of Clinical Neuroscience, HUBIN project, Karolinska Institutet and Hospital, Stockholm, Sweden; ⁶⁹Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center, Utrecht, The Netherlands; ⁷⁰Department of Psychiatry, Maastricht University Medical Centre, Maastricht, The Netherlands; ⁷¹Centre for Clinical Research in Neuropsychiatry (CCRN), Graylands Hospital, the University of Western Australia, Perth, WA, Australia; ⁷²Mental Health Sciences Unit and Institute of Cognitive Neuroscience, University College London, London, UK; ⁷³Department of Psychosis Studies, NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King's College, London, UK; ⁷⁴Neuropsychiatric Genetics Research Group, School of Medicine, Trinity College, Dublin, Ireland;

Epidemiological and genetic data support the notion that schizophrenia and bipolar disorder share genetic risk factors. In our previous genome-wide association study, meta-analysis and follow-up (totaling as many as 18 206 cases and 42 536 controls), we identified four loci showing genome-wide significant association with schizophrenia. Here we consider a mixed schizophrenia and bipolar disorder (psychosis) phenotype (addition of 7469 bipolar disorder cases, 1535 schizophrenia cases, 333 other psychosis cases, 808 unaffected family members and 46 160 controls). Combined analysis reveals a novel variant at 16p11.2 showing genome-wide significant association (rs4583255[T]; odds ratio = 1.08; $P = 6.6 \times 10^{-11}$). The new variant is located within a 593-kb region that substantially increases risk of psychosis when duplicated. In line with the association of the duplication with reduced body mass index (BMI), rs4583255[T] is also associated with lower BMI ($P = 0.0039$ in the public GIANT consortium data set; $P = 0.00047$ in 22 651 additional Icelanders).

Molecular Psychiatry advance online publication, 20 November 2012; doi:10.1038/mp.2012.157

Keywords: association; bipolar disorder; cross-disorder; schizophrenia; 16p11.2

INTRODUCTION

Two structural variants, a balanced t(1;11) translocation interrupting *DISC1* and a microdeletion at 22q11.2, were the first genetic polymorphisms to show compelling evidence of association with schizophrenia.^{1,2} More recently, additional microdeletions and microduplications conferring risk of schizophrenia and, in some cases, bipolar disorder have been uncovered.^{3–10} These copy number variants (CNVs) confer high-to-moderate relative risk, however, because they typically change copy number of multiple genes, and may also affect regulation of genes at their margins, they do not generally implicate individual genes.

Currently, common single nucleotide polymorphisms (SNPs) are convincing risk factors for schizophrenia and bipolar disorder, in addition to structural variants. Common alleles showing genome-wide significant association with at least one of the disorders have been found at more than 20 loci.^{11–29} None of these regions are within structural polymorphisms previously shown to be susceptibility factors for schizophrenia or bipolar disorder. Nevertheless, first principles and data from other disorders predict the existence of common variants conferring risk through the same genes as rare structural alleles.³⁰ The identification of common risk variants within CNV regions may aid in uncovering the causal gene or genes of a CNV, or help to elucidate other aspects of a CNV's association with disease.

Two loci have been reported to harbor common alleles showing genome-wide significant association with both schizophrenia and bipolar disorder.^{13,16,23,24} In addition, several common variants initially displaying genome-wide significant association with one of the disorders have been shown, in subsequent studies, to confer risk of the other.^{31,32} Investigations considering schizophrenia and bipolar disorder as a single phenotype also support shared risk alleles,^{16,19,22} and an overlapping polygenic component has been described by several studies.^{21,28} These data are consistent with current epidemiological investigations, which predict shared genetic risk factors for schizophrenia and bipolar disorder.³³

Previously, we carried out a schizophrenia genome-wide association (GWA) study, SGENE-plus, followed by meta-analysis

of the top 1500 results with data from the International Schizophrenia Consortium (ISC) and the Molecular Genetics of Schizophrenia (MGS) group.¹⁵ Loci having P -values $< 1 \times 10^{-4}$ (covered by 39 SNPs located in 33 genomic regions) were followed up in a data set of up to 10 260 schizophrenia cases and 23 500 controls.¹⁴ In this work, we broaden our phenotype of interest to psychosis (schizophrenia, bipolar disorder and related psychoses), examining the same group of follow-up SNPs in a data set augmented by 7469 bipolar disorder cases, 1535 schizophrenia cases, 333 other psychosis cases, 808 unaffected family members and 46 160 controls.

MATERIALS AND METHODS

Samples

The genome-wide typed ('SGENE-plus'; 2663 cases and 13 498 controls) and meta-analysis ('SGENE-plus + ISC + MGS') samples (in total, 7946 cases and 19 036 controls) used here were identical to those used in our previous schizophrenia GWA study and meta-analysis.¹⁵ The primary psychosis follow-up samples employed consisted of follow-up samples from our previous GWA follow-up study (9246 schizophrenia cases and 22 356 controls),¹⁴ plus an additional 9337 psychosis cases (1535 schizophrenia, 7469 bipolar disorder and 333 related psychoses) and 46 968 controls/unaffected family members. The primary follow-up samples were genotyped or imputed for all follow-up markers. The secondary follow-up samples consisted of 1014 cases and 1144 controls from the Göttingen Research Association for Schizophrenia^{34,35} study. These samples, which also had been used for secondary follow-up in our previous GWA follow-up study,¹⁴ were genotyped for SNPs that were genome-wide significant in the combined meta-analysis and primary follow-up samples. Table 1 summarizes the schizophrenia and psychosis data sets used in previous and current work, and Supplementary Table 1 includes details on the individual study groups. The autism samples (3773 cases, 16 103 controls, 4206 family members) derived from the Autism Genome Project, the Autism Genetic Resource Exchange and nine European study groups (Supplementary Table 2). Further information on ascertainment and diagnosis for the psychosis and autism samples is provided in the Supplementary Material.

⁷⁵Department of Psychiatry, Queens University, Belfast, UK; ⁷⁶Department of Human Genetics, Virginia Commonwealth University, Richmond, VA, USA; ⁷⁷Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA; ⁷⁸Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA;

⁷⁹MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK;

⁸⁰Genomic Medicine Group – Galician Foundation of Genomic Medicine-Biomedical Network Research Centre on Rare Diseases (CIBERER), University of Santiago de Compostela, Santiago de Compostela, Spain; ⁸¹Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark; ⁸²National Centre for Register-based Research, Aarhus University, Aarhus, Denmark; ⁸³German Center for Neurodegenerative Disorders (DZNE), Bonn Germany; ⁸⁴Institute of Human Genetics, University of Bonn, Bonn Germany; ⁸⁵Institute of Neurosciences and Medicine (INM-1), Juelich, Germany; ⁸⁶Section of Psychiatry, University of Verona, Verona, Italy; ⁸⁷Program in Medical and Population Genetics and Genetic Analysis Platform, The Broad Institute of MIT and Harvard, Cambridge, MA, USA; ⁸⁸Department of Medical Genetics, University of Helsinki and University Central Hospital, Helsinki, Finland; ⁸⁹Department of Psychiatry, University of Halle-Wittenberg, Halle, Germany and ⁹⁰Eli Lilly and Co. Ltd, Erl Wood Manor, Windlesham, Surrey, UK. Correspondence: Dr K Stefansson, deCODE genetics, Sturlugata 8, Reykjavik IS-101, Iceland,

E-mail: kstefans@decode.is

⁹¹see Appendix.

Received 27 June 2012; revised 14 September 2012; accepted 17 September 2012

Table 1. Schizophrenia and psychosis data sets used in previous and current work

Data set	Case phenotype	Markers examined	N		Initial use	Overlap with other sets
			Cases	Controls + family members		
SGENE-plus GWAS	SZ	314 868	2663	13 498	Stefansson ¹⁵	No
SGENE-plus + ISC + MGS	SZ	1500	7946	19 036	Stefansson ¹⁵	Includes SGENE-plus GWAS
Primary schizophrenia follow-up	SZ	39	9246	22 356	Steinberg ¹⁴	No
Primary psychosis follow-up	SZ, BP, other psychosis	39	18 583	69 324	This work	Includes primary schizophrenia follow-up
Secondary follow-up	SZ	8; 1 ^a	1014	1144	Steinberg ¹⁴	No

Abbreviations: BP, bipolar disorder; GWAS, genome-wide association study; ISC, International Schizophrenia Consortium; MGS, molecular genetics of schizophrenia; SZ, schizophrenia.

^aEight markers were examined in this set in the previous work,¹⁴ and an additional marker is genotyped in the current work.

Genotyping and association analysis

Genotyping was carried out using Illumina (San Diego, CA, USA) and Affymetrix genome-wide arrays (Santa Clara, CA, USA), Nanogen (San Diego, CA, USA) Centaurus assays, Taqman assays, the Sequenom MassArray iPLEX genotyping system (San Diego, CA, USA) and the Roche LightCycler480 system (Mannheim, Germany) (Supplementary Tables 1 and 2). Quality control and imputation were performed, by study group, as described in the Supplementary Methods. Case-control or family-based association analyses were carried out for each study group. For the case-control analyses, population stratification was controlled for using genomic control or principal components. Summary statistics from the various study groups were combined as described previously.¹⁵ Body mass index (BMI) measurements were adjusted for age and sex, and inverse standard normal transformed. Analysis was carried out by regressing the adjusted, transformed data on rs4583255[T] count.

Expression analysis

For the three brain data sets,^{36–38} expression levels were inverse normal transformed and regressed on the number of rs4583255-T alleles with gender, age at death, post-mortem interval, brain source, expression experiment batch, pH (Colantuoni *et al.*³⁶ only), sample expression level based on the total number of transcripts detected (Webster *et al.*³⁸ only) and Alzheimer's disease patient status (Webster *et al.*³⁸ only) as covariates. To incorporate data from different brain regions (Gibbs *et al.*³⁷) or different probes (*KCTD13* in Colantuoni *et al.*³⁶) derived from the same individual, a mixed-effects model with individual as a random effect was used. Results from the three data sets were combined using inverse-variance weighted meta-analysis. The Dutch whole-blood data set included control samples from two studies.^{39,40} Analysis was performed using linear regression in Plink⁴¹ taking age and gender as covariates. The Icelandic blood data set has been described previously,⁴² and analysis was carried out as detailed in that work.⁴²

RESULTS

We assembled a psychosis (schizophrenia, bipolar disorder and related psychoses) primary follow-up data set made up of 36 study groups containing a total of 18 583 cases, 68 516 controls and 808 unaffected family members (Supplementary Table 1). In each study group, allelic association analysis was carried out for 39 SNPs from 33 genomic regions (these SNPs covered P -values $< 1 \times 10^{-4}$ in the SGENE-plus + ISC + MGS meta-analysis at $r^2 = 0.3$). Results from the various study groups were combined using inverse-variance weighted meta-analysis.

At 31 of the 33 loci, odds ratios (ORs) in the psychosis follow-up group were in the same direction as in the discovery data set (SGENE-plus + ISC + MGS) (Supplementary Table 3). A similar pattern had been observed in the schizophrenia follow-up set—ORs were in the same direction at 30 of the 33 loci.¹⁴ These results

indicate that the set of variants chosen for follow-up was enriched for risk alleles ($P = 7.0 \times 10^{-7}$ for schizophrenia; $P = 6.5 \times 10^{-8}$ for psychosis).

Next, we performed a joint analysis of the discovery and psychosis follow-up sets. To account for testing two phenotypes (schizophrenia and psychosis), the genome-wide significance threshold was set at $P < (5 \times 10^{-8})/2$, or 2.5×10^{-8} . Five SNPs, residing at three loci, exceeded this threshold (Supplementary Table 3). Two of the loci—the major histocompatibility complex region and 11q21.2 near *NRGN*—had been genome-wide significant in the previous schizophrenia analysis; a third locus, in *TAOK2* at 16p11.2, was novel (Supplementary Table 3). Following the addition of data from a further 1014 schizophrenia cases and 1144 controls, the variant at the novel locus, rs4583255[T], was associated with psychosis with increased significance (OR = 1.08, $P = 6.6 \times 10^{-11}$, Table 2, Figure 1). rs4583255[T]'s association with psychosis fit the multiplicative model ($P = 0.42$), and there was no evidence of OR heterogeneity ($P = 0.71$; $I^2 = 0$; Supplementary Table 4).

In examination of the follow-up samples by diagnosis, the novel variant, rs4583255[T], showed significant association with both schizophrenia and bipolar disorder ($P = 0.0011$ and 0.00026 , respectively), with OR of 1.06 and 1.08, respectively (independent controls were used for the two analyses; see Supplementary Table 5). We also investigated association with bipolar disorder for variants that had shown genome-wide significant association with schizophrenia in our previous study.¹⁴ Following correction for eight tests, rs12807809[T], near *NRGN*, was significantly associated with bipolar disorder ($P = 0.0023$) with an OR identical to that of the schizophrenia follow-up samples (OR = 1.09). The remaining schizophrenia susceptibility variants did not show even nominally significant association with bipolar disorder—yet, OR confidence intervals for the two disorders overlapped for at least some variants at all loci (Supplementary Table 5).

Intriguingly, the newly identified SNP is located in a nearly 600-kb region that confers risk of schizophrenia and bipolar disorder when duplicated (Figure 1).^{5,6,28} Copy number gain of the region also is associated with autism,^{6,43–45} reduced head circumference^{46,47} and low BMI.⁴⁷ We obtained large data sets to examine association of rs4583255[T] with both autism and BMI. Based on 3773 cases, 16 103 controls and 4206 unaffected family members from the Autism Genetic Resource Exchange, the Autism Genome Project and nine European study groups (Supplementary Table 2), we found no evidence of association with autism spectrum disorder (ASD), strict autism or multiplex ASD (ASD, OR = 1.00, $P = 0.98$; strict autism, OR = 1.02, $P = 0.66$; multiplex ASD, OR = 1.07, $P = 0.22$; Supplementary Table 6), although power




Figure 1. Association results and structure of the 16p11.2 region. Bars on the x-axis indicate segmental duplications (brown) and recombination hotspots (pink). Association results are illustrated for SGENE-plus (black), SGENE-plus + MGS + ISC (green), SGENE-plus + MGS + ISC plus the primary psychosis follow-up (blue) and SGENE-plus + MGS + ISC plus the primary psychosis and secondary schizophrenia follow-up (red). RefSeq genes in the region are shown below the plot.

Table 2. Genome-wide significant association of rs4583255[T] with psychosis

Study group	N			OR (95% CI)	P-value
	Cases	Controls	Family members		
SGENE-plus + ISC + MGS	7946	19 036	0	1.10 (1.05, 1.15)	2.5×10^{-5}
Primary psychosis follow-up	18 583	68 516	808	1.07 (1.04, 1.10)	9.2×10^{-7}
Secondary follow-up	1014	1144	0	1.10 (0.97, 1.24)	0.14
Combined	27 543	88 696	808	1.08 (1.05, 1.10)	6.6×10^{-11}

Abbreviations: CI, confidence interval; ISC, International Schizophrenia Consortium; MGS, Molecular Genetics of Schizophrenia; OR, odds ratio.

to detect association at the OR found in the follow-up psychosis samples was modest (at a 0.05 significance level, power was about 57% for ASD, 42% for strict autism and 23% for multiplex ASD). In contrast, we found significant association of rs4583255[T] with lower BMI in the published GIANT consortium GWAS data set of 123 865 individuals⁴⁸ ($P=0.0039$) and in 22 651 Icelanders who were not included in the GIANT study ($P=0.00047$).

Recently, a study examining the effect of altered expression of 16p11.2 CNV region genes on zebrafish head size identified *KCTD13* as the major driver of head size change, with *MAPK3* and *MVP* named as possible modifiers.⁴⁹ These results motivated us to examine association of rs4583255[T] with expression of *KCTD13*, *MAPK3* and *MVP* in human brain. Using data from three publicly available data sets with at least 50 European-ancestry adult brains each (total $N=565$),^{36–38} we found that rs4583255[T] was significantly associated with expression of *MAPK3* (effect = 0.12 s.d.; $P=0.011$), but not significantly associated with expression of *KCTD13* or *MVP* (Supplementary Table 7). We also investigated association of rs4583255[T] with gene expression in blood using data sets from Iceland ($N=972$)⁴² and the Netherlands ($N=437$).^{39,40} Consistent with the brain results, rs4583255[T] was significantly associated with higher expression of *MAPK3* (for Iceland, $P=9.4 \times 10^{-15}$; for the Netherlands, $P=0.014$ for probe 3870601, and $P=0.042$ for probe 234040), but not significantly associated with expression of *KCTD13* or *MVP*.

DISCUSSION

In this study, we uncovered a novel variant at 16p11.2, rs4583255[T], showing genome-wide significant association with psychosis (OR = 1.08; $P=6.6 \times 10^{-11}$). In follow-up samples, ORs were similar for schizophrenia and bipolar disorder (OR = 1.06 and 1.08, respectively), and association was significant for both ($P=0.0011$ and 0.00026 , respectively). Thus, rs4583255[T] is a compelling example of a genetic variant that confers risk across traditional diagnostic boundaries.

Among the variants that showed genome-wide significant association with schizophrenia in our previous study,¹⁴ only rs12807809[T] showed significant association with bipolar disorder in the current work. Nevertheless, OR confidence intervals for schizophrenia and bipolar disorder overlapped for most risk alleles. Very large data sets will be necessary to establish conclusively where these variants fall on the spectrum of conferring risk of one disorder, exclusively, to conferring equal risk of either.

To our knowledge, this is the first case in which a common risk allele showing genome-wide significant association with psychosis has turned out to be located within a CNV that had been previously associated with psychosis. Both copy number gain and loss of the 16p11.2 region are associated with multiple phenotypes. Duplication is associated with psychosis,^{5,6,28} both copy number gain and loss are associated with autism and developmental delay,^{6,43–45} and duplication and deletion lead to

reduction and enlargement, respectively, of head circumference and BMI.^{46,47}

In this work, we found that rs4583255[T] also confers risk of reduced BMI ($P=0.0039$ in GIANT; $P=0.00047$ in additional Icelanders). This result supports the suggestion, made previously,⁴⁷ that the effects of duplication on psychosis and BMI have a single origin, presumably in the brain. We did not find evidence of association of rs4583255[T] with autism, although we were somewhat underpowered to detect an effect of the same size as in psychosis, especially, for sub-phenotypes.

We found that rs4583255[T] was associated with increased expression in adult brain and blood of *MAPK3*, one of the 16p11.2 genes identified as involved in causing head-circumference changes in zebrafish.⁴⁹ Caution is required in interpretation of this result, however, as the significance in brain is not overwhelming and, furthermore, gene expression in the pre-adult brain may be most relevant for the development of psychosis. Data from only extremely small numbers of European-ancestry brains at pre-adult stages were available, precluding investigation of the association of rs4583255[T] with gene expression at these stages.

In conclusion, in this work, we broadened our phenotype of interest to psychosis, identifying a new common risk allele, rs4583255[T], with similar ORs for schizophrenia and bipolar disorder. The novel variant is located within a duplication previously associated with psychosis, and, in line with the duplication's effects, also is associated with lower BMI. In the future, knowledge of this common variant association may prove useful to studies aimed at further understanding the mechanism through which the duplication exerts its effects on neurodevelopmental and anthropomorphic phenotypes.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We would like to thank the subjects, their families and the recruitment centre staff. We would also like to acknowledge the help of Maria Dolores Moltó (Genetics Department, Valencia University, CIBERSAM), Eduardo Paz and Ramón Ramos-Ríos (Complejo Hospitalario de Santiago), and the contribution of Fundación Botín. This study makes use of seven external, publicly available data sets. First, it makes use of data generated by the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project whose principal investigators were Jeffrey A Lieberman, MD, T Scott Stroup, MD, MPH, and Joseph P McEvoy, MD. The CATIE trial was funded by a grant from the National Institute of Mental Health (N01 MH900001) along with MH074027 (PI PF Sullivan). Genotyping was funded by Eli Lilly and Company. Second, the GAIN/BiGs data sets used in this work were obtained from the database of Genotypes and Phenotypes (dbGaP) found at <http://www.ncbi.nlm.nih.gov/gap> through dbGaP accession number phs000017.v3.p1. Third, the study uses samples genotyped using the Illumina 550K platform by the Pritzker Consortium, supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. The Pritzker Consortium includes scientists at the University of Michigan (H Akil and S J Watson, Site Directors, and Michael Boehnke, lead on bipolar genotyping effort); Stanford University (Rick Myers and Alan Schatzberg, Site Directors); the University of California at Davis (Ted Jones, Site Director); the University of California at Irvine (William Bunney, Site Director); and the Weill Medical College of Cornell University (Jack Barchas, Site Director). Fourth, the work uses data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) project, led by Gary Sachs, MD, and coordinated by Massachusetts General Hospital in Boston, MA (NIMH grant number was 2N01MH080001-001). Fifth, this study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113 and 085475. Sixth, we gratefully acknowledge the resources provided by the Autism Genetic Resource Exchange (AGRE) Consortium* and the participating AGRE families. The AGRE is a program of Autism Speaks and is supported, in part, by grant 1U24MH081810 from the National Institute of Mental Health to Clara M Lajonchere (PI). Seventh, the Autism Genome Project (AGP) data sets used for the analysis described in this manuscript were obtained from dbGaP at <http://www.ncbi.nlm.nih.gov/gap> through dbGaP accession number,

phs000267.v1.p1. Submission of the data to dbGaP was provided by Dr Bernie Devlin on behalf of the AGP. Collection and submission of the data to dbGaP were supported by a grant from the Medical Research Council (G0601030) and the Wellcome Trust (075491/Z/04), Anthony P Monaco, PI, University of Oxford. This work was also supported by the European Union (grant numbers LSMM-CT-2006-037761 (Project SGENE), PIAP-GA-2008-218251 (Project PsychGene), HEALTH-F2-2009-223423 (Project PsychCNVs), HEALTH-F4-2009-242257 (Project ADAMS) and IMI-JU-New-Meds); the National Genome Research Network of the German Federal Ministry of Education and Research (BMBF) (grant numbers 01GS08144 (MooDS-Net) and 01GS08147 (NGFNplus)); the National Institute of Mental Health (R01 MH078075, and N01 MH900001, MH074027 to the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project); the Centre of Excellence for Complex Disease Genetics of the Academy of Finland (grant numbers 213506 and 129680); the Biocentrum Helsinki Foundation and Research Program for Molecular Medicine, Faculty of Medicine, University of Helsinki; the Stanley Medical Research Institute; the Danish Council for Strategic Research (grant number 2101-07-0059); H Lundbeck A/S; the Research Council of Norway (grant number 163070/V50); the Danish Medical Research Council; the South-East Norway Health Authority (grant number 2004-123); the Medical Research Council; Ministerio de Sanidad y Consumo, Spain (grant number PI081522 to JC); Xunta de Galicia (grant number 08CSA005208PR to A Carracedo); the Swedish Research Council; the Wellcome Trust (Wellcome Trust grants 085475/B/08/Z and 085475/Z/08/Z as part of the Wellcome Trust Case Control Consortium 2); the Max Planck Society; Saarland University (grant number T6 03 10 00-45 to CMF); the Netherlands Foundation for Brain Research (Hersenstichting) (grant number 2008(1).34 to M Poot); and Eli Lilly and Company (genotyping for CATIE and part of the TOP sample). For further acknowledgements, see the Supplementary Material.

REFERENCES

- Chubb JE, Bradshaw NJ, Soares DC, Porteous DJ, Millar JK. The DISC locus in psychiatric illness. *Mol Psychiatry* 2008; **13**: 36–64.
- Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J *et al*. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. *Proc Natl Acad Sci USA* 1995; **92**: 7612–7616.
- Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietilainen OP *et al*. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. *Mol Psychiatry* 2011; **16**: 17–25.
- International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. *Nature* 2008; **455**: 237–241.
- Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J *et al*. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. *Am J Psychiatry* 2011; **168**: 302–316.
- McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S *et al*. Microduplications of 16p11.2 are associated with schizophrenia. *Nat Genet* 2009; **41**: 1223–1227.
- Mulle JG, Dodd AF, McGrath JA, Wolyniec PS, Mitchell AA, Shetty AC *et al*. Microdeletions of 3q29 confer high risk for schizophrenia. *Am J Hum Genet* 2010; **87**: 229–236.
- Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, Touloupoulou T *et al*. Disruption of the neurexin 1 gene is associated with schizophrenia. *Hum Mol Genet* 2009; **18**: 988–996.
- Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S *et al*. Large recurrent microdeletions associated with schizophrenia. *Nature* 2008; **455**: 232–236.
- Vacic V, McCarthy S, Malhotra D, Murray F, Chou HH, Peoples A *et al*. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. *Nature* 2011; **471**: 499–503.
- Yue WH, Wang HF, Sun LD, Tang FL, Liu ZH, Zhang HX *et al*. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. *Nat Genet* 2011; **43**: 1228–1231.
- Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L *et al*. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. *Mol Psychiatry* 2011; **16**: 429–441.
- Vassos E, Steinberg S, Cichon S, Breen G, Sigurdsson E, Andreassen OA *et al*. Replication study and meta-analysis in European samples supports association of the 3p21.1 locus with bipolar disorder. *Biol Psychiatry* 2012; **72**: 645–650.
- Steinberg S, de Jong S, Andreassen OA, Werge T, Borglum AD, Mors O *et al*. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. *Hum Mol Genet* 2011; **20**: 4076–4081.
- Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D *et al*. Common variants conferring risk of schizophrenia. *Nature* 2009; **460**: 744–747.
- Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N *et al*. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nat Genet* 2011; **43**: 977–983.

- 17 Shi Y, Li Z, Xu Q, Wang T, Li T, Shen J et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. *Nat Genet* 2011; **43**: 1224–1227.
- 18 Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. *Nature* 2009; **460**: 753–757.
- 19 Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA et al. Genome-wide association study identifies five new schizophrenia loci. *Nat Genet* 2011; **43**: 969–976.
- 20 Rietschel M, Mattheisen M, Degenhardt F, Kahn RS, Linszen DH, Os JV et al. Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. *Mol Psychiatry* 2012; **17**: 906–917.
- 21 Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 2009; **460**: 748–752.
- 22 O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. *Nat Genet* 2008; **40**: 1053–1055.
- 23 McMahon FJ, Akula N, Schulze TG, Muglia P, Tozzi F, Detera-Wadleigh SD et al. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. *Nat Genet* 2010; **42**: 128–131.
- 24 Hamshere ML, Walters JT, Smith R, Richards AL, Green E, Grozeva D et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. *Mol Psychiatry* 2012.
- 25 Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. *Nat Genet* 2008; **40**: 1056–1058.
- 26 Cichon S, Muhleisen TW, Degenhardt FA, Mattheisen M, Miro X, Strohmaier J et al. Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. *Am J Hum Genet* 2011; **88**: 372–381.
- 27 Chen DT, Jiang X, Akula N, Shugart YY, Wendland JR, Steele CJ et al. Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder. *Mol Psychiatry* 2011.
- 28 Bergen SE, O'Dushlaine CT, Ripke S, Lee PH, Ruderfer DM, Akterin S et al. Genome-wide association study in a Swedish population yields support for greater CNV and major histocompatibility complex involvement in schizophrenia compared with bipolar disorder. *Mol Psychiatry* 2012; **17**: 880–886.
- 29 Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. *Mol Psychiatry* 2008; **13**: 197–207.
- 30 Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. *Science* 2008; **322**: 881–888.
- 31 Muhleisen TW, Mattheisen M, Strohmaier J, Degenhardt F, Priebe L, Schultz CC et al. Association between schizophrenia and common variation in neurocan (NCAN), a genetic risk factor for bipolar disorder. *Schizophr Res* 2012; **138**: 69–73.
- 32 Williams HJ, Craddock N, Russo G, Hamshere ML, Moskvina V, Dwyer S et al. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. *Hum Mol Genet* 2011; **20**: 387–391.
- 33 Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet* 2009; **373**: 234–239.
- 34 Papiol S, Begemann M, Rosenberger A, Friedrichs H, Ribbe K, Grube S et al. A phenotype-based genetic association study reveals the contribution of neuregulin1 gene variants to age of onset and positive symptom severity in schizophrenia. *Am J Med Genet B Neuropsychiatr* 2011; **156B**: 340–345.
- 35 Ribbe K, Friedrichs H, Begemann M, Grube S, Papiol S, Kastner A et al. The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. *BMC Psychiatry* 2010; **10**: 91.
- 36 Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. *Nature* 2011; **478**: 519–523.
- 37 Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL et al. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. *PLoS Genet* 2010; **6**: e1000952.
- 38 Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P et al. Genetic control of human brain transcript expression in Alzheimer disease. *Am J Hum Genet* 2009; **84**: 445–458.
- 39 Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A et al. Multiple common variants for celiac disease influencing immune gene expression. *Nat Genet* 2010; **42**: 295–302.
- 40 Saris CG, Horvath S, van Vught PW, van Es MA, Blauw HM, Fuller TF et al. Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients. *BMC Genomics* 2009; **10**: 405.
- 41 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81**: 559–575.
- 42 Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J et al. Genetics of gene expression and its effect on disease. *Nature* 2008; **452**: 423–428.
- 43 Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R et al. Association between microdeletion and microduplication at 16p11.2 and autism. *N Engl J Med* 2008; **358**: 667–675.
- 44 Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J et al. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet* 2008; **82**: 477–488.
- 45 Kumar RA, KaraMohamed S, Sudi J, Conrad DF, Brune C, Badner JA et al. Recurrent 16p11.2 microdeletions in autism. *Hum Mol Genet* 2008; **17**: 628–638.
- 46 Shinawi M, Liu P, Kang SH, Shen J, Belmont JW, Scott DA et al. Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. *J Med Genet* 2010; **47**: 332–341.
- 47 Jacquemont S, Reymond A, Zufferey F, Harewood L, Walters RG, Kutalik Z et al. Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. *Nature* 2011; **478**: 97–102.
- 48 Shinawi M, Liu P, Belmont JW, Belmont JW, Scott DA et al. Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. *J Med Genet* 2010; **47**: 332–341.
- 49 Golzio C, Willer J, Talkowski ME, Oh EC, Taniguchi Y, Jacquemont S et al. KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. *Nature* 2012; **485**: 363–367.

Supplementary Information accompanies the paper on the Molecular Psychiatry website (<http://www.nature.com/mp>)

APPENDIX

GENETIC RISK AND OUTCOME IN PSYCHOSIS (GROUP)

René S. Kahn¹, Don H. Linszen², Jim van Os³, Durk Wiersma⁴, Richard Bruggeman⁴, Wiepke Cahn¹, Lieuwe de Haan², Lydia Krabbendam³ and Inez Myin-Germeys³

¹Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Postbus 85060, Utrecht, The Netherlands

²Academic Medical Centre University of Amsterdam, Department of Psychiatry, Amsterdam, NL326 Groot-Amsterdam, The Netherlands

³Maastricht University Medical Centre, South Limburg Mental Health Research and Teaching Network, 6229 HX Maastricht, The Netherlands

⁴University Medical Center Groningen, Department of Psychiatry, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands

WELLCOME TRUST CASE CONTROL CONSORTIUM 2

Management committee

Peter Donnelly (Chair)^{1,2}, Ines Barroso (Deputy Chair)³, Jenefer M Blackwell^{4,5}, Elvira Bramon⁶, Matthew A Brown⁷, Juan P Casas⁸, Aiden Corvin⁹, Panos Deloukas³, Audrey Duncanson¹⁰, Janusz Jankowski¹¹, Hugh S Markus¹², Christopher G Mathew¹³, Colin NA Palmer¹⁴, Robert Plomin¹⁵, Anna Rautanen¹, Stephen J Sawcer¹⁶, Richard C Trembath¹³, Ananth C Viswanathan¹⁷ and Nicholas W Wood¹⁸

Data and analysis group

Chris C A Spencer¹, Gavin Band¹, Céline Bellenguez¹, Colin Freeman¹, Garrett Hellenthal¹, Eleni Giannoulidou¹, Matti Pirinen¹, Richard Pearson¹, Amy Strange¹, Zhan Su¹, Damjan Vukcevic¹ and Peter Donnelly^{1,2}

DNA, genotyping, data QC and informatics group

Cordelia Langford³, Sarah E Hunt³, Sarah Edkins³, Rhian Gwilliam³, Hannah Blackburn³, Suzannah J Bumpstead³, Serge Dronov³, Matthew Gillman³, Emma Gray³, Naomi Hammond³, Alagurevathi Jayakumar³, Owen T McCann³, Jennifer Liddle³, Simon C Potter³, Radhi Ravindrarajah³, Michelle Ricketts³, Matthew Waller³, Paul Weston³, Sara Widaa³, Pamela Whittaker³, Ines Barroso³ and Panos Deloukas³.

Publications committee

Christopher G Mathew (Chair),¹³ Jenefer M Blackwell^{4,5}, Matthew A Brown⁷, Aiden Corvin⁹ and Chris C A Spencer¹

¹Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK

²Department of Statistics, University of Oxford, Oxford OX1 3TG, UK

³Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK

⁴Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, 100 Roberts Road, Subiaco, Western Australia 6008, Australia

⁵Cambridge Institute for Medical Research, University of Cambridge School of Clinical Medicine, Cambridge CB2 0XY, UK

⁶Department of Psychosis Studies, NIHR Biomedical Research Centre for Mental Health at the Institute of Psychiatry, King's College London and The South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AF, UK

⁷University of Queensland Diamantina Institute, Brisbane, Queensland, Australia

⁸Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK, and Department Epidemiology and Public Health, University College London WC1E 6BT, UK

⁹Neuropsychiatric Genetics Research Group, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland

¹⁰Molecular and Physiological Sciences, The Wellcome Trust, London NW1 2BE, UK

¹¹Department of Oncology, Old Road Campus, University of Oxford, Oxford OX3 7DQ, UK, Digestive Diseases Centre, Leicester Royal Infirmary, Leicester LE7 7HH, UK, and Centre for Digestive Diseases, Queen Mary University of London, London E1 2AD, UK

¹²Clinical Neurosciences, St George's University of London, London SW17 0RE, UK

¹³King's College London Dept Medical and Molecular Genetics, King's Health Partners, Guy's Hospital, London SE1 9RT, UK

¹⁴Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK

¹⁵King's College London Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Denmark Hill, London SE5 8AF, UK

¹⁶Department of Clinical Neurosciences, University of Cambridge Addenbrooke's Hospital, Cambridge CB2 0QQ, UK

¹⁷NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, UK

¹⁸Department of Molecular Neuroscience, Institute of Neurology, Queen Square, London WC1N 3BG, UK.